August 3, 2020

The 2019 Annual Report on Form 10-K of Aduro Biotech, Inc. (the "Company") for the year ended December 31, 2019 has been filed with the SEC electronically through the Internet on March 3, 2020. The information contained in the 2019 Annual Report on Form 10-K is incorporated by reference into this Current Report on Form 8-K.


The Company's website contains valuable information about the Company's business, results of operations and financial condition. The Company encourages you to visit its website and review the information it contains.

ADURO BIOTECH, INC.
Completed Response to Stimulation of STING in Human Cancer Models

In the "Investor Relations" section, copies of materials that Aduro files with, or furnishes to, the SEC, are available, free of charge, on the Company's website at http://www.aduro.com.

This communication does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to purchase any Aduro or Chinook securities. Security holders may receive solicitation materials from the Company and Chinook concerning the proposed merger. Security holders are not required to pay any fee to receive solicitation materials. Additional information regarding the interests of such individuals in the proposed merger will be included in the definitive proxy statement to be filed with the SEC. Security holders are urged to read such materials carefully when they become available because they will contain important information.

Security holders may obtain copies of the preliminary proxy statement/prospectus and other documents relating to the proposed transaction from the SEC at http://www.sec.gov, or request that copies be sent to them at the address of the Company's Investor Relations Department, at 3180 Tassafaronga Place, Suite 100, Berkeley, CA 94705, or by contacting the Company's Investor Relations Department at press@aduro.com.

Additional Information Concerning the Proposed Transaction

The Company will file with the SEC a definitive proxy statement and, if applicable, a definitive merger agreement in connection with the proposed transaction. The Company's security holders and other interested persons are urged to read the definitive proxy statement (which will be available free of charge in the manner described under "Additional Information Concerning the Proposed Transaction" above) and other documents relating to the proposed transaction that will be filed with the SEC, as these documents will contain important information.

The Company, Chinook and their respective directors and officers may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the proposed transaction. Information about the Company's directors and executive officers may be found in Aduro's proxy statement for its 2019 annual meeting of stockholders, which was filed with the SEC on March 9, 2020.

Additional information regarding the interests of such individuals in the proposed merger will be included in the definitive proxy statement to be filed with the SEC. Security holders are urged to read such materials carefully when they become available because they will contain important information.

Additional disclosure of the material terms of the proposed transaction is included under the heading "Risk Factors" contained in our quarterly report on Form 10-Q for the quarter ended June 30, 2020.

The Company's and Chinook's financial statements are included in the 2019 Annual Report on Form 10-K that was filed with the SEC on March 3, 2020, and the readers are encouraged to carefully review and evaluate the financial information contained in such reports.

The information provided in this report is not intended to be a substitute for reading the Company's and Chinook's respective 2019 Annual Reports on Form 10-K, which contain more complete information and are available at www.sec.gov.

The information provided in this report does not purport to be complete or inclusive and should not be considered as the sole basis of any decision in connection with the proposed transaction. Neither the Company nor Chinook makes any representations as to the accuracy or completeness of any information or forecasts contained herein or makes any representation with respect to the accuracy or completeness of the financial data and other information contained herein.

This communication speaks for the date it is made, and the Company and Chinook assume no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

This communication contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may be identified by words such as "may," "will," "expect," "project," "anticipate," "plan," "intend," "believe," "estimate," "potential," "future," "could," "should," or similar expressions, are based on current expectations, estimates, forecasts and projections about the industry in which the Company operates, and the Company’s current beliefs and assumptions, as of the date of this communication. The Company’s actual results may differ from these statements.

This communication includes a number of forward-looking statements regarding the proposed merger and Aduro’s business, financial condition and results of operations. Forward-looking statements are subject to risks and uncertainties and actual results could differ materially from those expressed in, or implied by, such forward-looking statements. In addition to the factors described under "Risk Factors" contained in our and Chinook’s respective annual reports on Form 10-K, other factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements include: the outcome of pending litigation; the ability to obtain necessary financing or adequate capital resources for our operations; the ability to obtain necessary regulatory approvals, including full approval by the U.S. Food and Drug Administration, or FDA, for our product candidates in a timely manner; the ability to successfully conduct clinical trials for our product candidates and the timing of such clinical trials, the results of which may not be positive or may not support commercialization of our product candidates; the timing and results of our preclinical studies and ongoing clinical trials of our product candidates; our ability to file and obtain necessary regulatory approvals for our product candidates; the outcome of litigation or other legal proceedings; the ability to obtain adequate intellectual property protection for our product candidates; our ability to establish, maintain and protect our intellectual property rights; and other risks and uncertainties that are described in the "Risk Factors" section in our and Chinook’s respective annual reports on Form 10-K.

The forward-looking statements contained in this communication speak only as of their date. The Company and Chinook undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should be read in conjunction with the information included in the Company’s and Chinook’s respective 2019 Annual Reports on Form 10-K, which contain more complete information and are available at www.sec.gov.

The Company may not conduct any further business prior to the completion of the proposed transaction, the terms of which are subject to change, and the Company may be required to conduct additional due diligence in connection with the proposed transaction.

The Company does not undertake to update any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should be read in conjunction with the information included in the Company’s and Chinook’s respective 2019 Annual Reports on Form 10-K, which contain more complete information and are available at www.sec.gov.